Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911729 · ClinicalTrials.gov registry record
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
A clinical trial, sponsored by Molecular Insight Pharmaceuticals.
- Terminated
- Registry status
- 24
- Enrollment target
NCT00911729: Clinical Trial study, sponsored by Molecular Insight Pharmaceuticals.
NCT00911729 is a clinical trial that was terminated before completion, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911729 was terminated before completion, sponsored by Molecular Insight Pharmaceuticals.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-04 |
Why NCT00911729 stopped before completion
NCT00911729 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00911729 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00911729 about?
NCT00911729 is a clinical study titled "Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma". The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.
What is the current status of trial NCT00911729?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2009-04.
Who is sponsoring clinical trial NCT00911729?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia